BACKGROUND: Tolebrutinib is an oral, CNS-penetrant, irreversible inhibitor of Bruton's tyrosine kinase, an enzyme expressed in B lymphocytes and myeloid cells including microglia, which are major drivers of inflammation in multiple sclerosis. We aimed to determine the dose-response relationship between tolebrutinib and the reduction in new active brain MRI lesions in patients with relapsing multiple sclerosis. METHODS: We did a 16-week, phase 2b, randomised, double-blind, placebo-controlled, crossover, dose-finding trial at 40 centres (academic sites, specialty clinics, and general neurology centres) in ten countries in Europe and North America. Eligible participants were adults aged 18-55 years with diagnosed relapsing multiple sclerosis (either relapsing-remitting or relapsing secondary progressive multiple sclerosis), and one or more of the following criteria: at least one relapse within the previous year, at least two relapses within the previous 2 years, or at least one active gadolinium-enhancing brain lesion in the 6 months before screening. Exclusion criteria included a diagnosis of primary progressive multiple sclerosis or a diagnosis of secondary progressive multiple sclerosis without relapse. We used a two-step randomisation process to randomly assign eligible participants (1:1) to two cohorts, then further randomly assign participants in each cohort (1:1:1:1) to four tolebrutinib dose groups (5, 15, 30, and 60 mg administered once daily as an oral tablet). Cohort 1 received tolebrutinib for 12 weeks, then matched placebo (ie, identical looking tablets) for 4 weeks; cohort 2 received 4 weeks of placebo followed by 12 weeks of tolebrutinib. Participants and investigators were masked for dose and tolebrutinib-placebo administration sequence; investigators, study team members, and study participants did not have access to unmasked data. MRI scans were done at screening and every 4 weeks over 16 weeks. The primary efficacy endpoint was the number of new gadolinium-enhancing lesions detected on the scan done after 12 weeks of tolebrutinib treatment (assessed at week 12 for cohort 1 and week 16 for cohort 2), relative to the scan done 4 weeks previously, and compared with the lesions accumulated during 4 weeks of placebo run-in period in cohort 2. Efficacy data were analysed in a modified intention-to-treat population, using a two-step multiple comparison procedure with modelling analysis. Safety was assessed for all participants who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov (NCT03889639), EudraCT (2018-003927-12), and WHO (U1111-1220-0572), and has been completed. FINDINGS: Between May 14, 2019, and Jan 2, 2020, we enrolled and randomly assigned 130 participants to tolebrutinib: 33 to 5 mg, 32 to 15 mg, 33 to 30 mg, and 32 to 60 mg. 129 (99%) completed the treatment regimen and 126 were included in the primary analysis. At treatment week 12, there was a dose-dependent reduction in the number of new gadolinium-enhancing lesions (mean [SD] lesions per patient: placebo, 1·03 [2·50]; 5 mg, 1·39 [3·20]; 15 mg, 0·77 [1·48]; 30 mg, 0·76 [3·31]; 60 mg, 0·13 [0·43]; p=0·03). One serious adverse event was reported (one patient in the 60 mg group was admitted to hospital because of a multiple sclerosis relapse). The most common non-serious adverse event during tolebrutinib treatment was headache (in one [3%] of 33 in the 5 mg group; three [9%] of 32 in the 15 mg group; one [3%] of 33 in the 30 mg group; and four [13%] of 32 in the 60 mg group). No safety-related discontinuations or treatment-related deaths occurred. INTERPRETATION: 12 weeks of tolebrutinib treatment led to a dose-dependent reduction in new gadolinium-enhancing lesions, the 60 mg dose being the most efficacious, and the drug was well tolerated. Reduction of acute inflammation, combined with the potential to modulate the immune response within the CNS, provides a scientific rationale to pursue phase 3 clinical trials of tolebrutinib in patients with relapsing and progressive forms of multiple sclerosis. FUNDING: Sanofi.

Center for Neuroinflammation and Neurotherapeutics and the Department of Neurology University of Pennsylvania Philadelphia PA USA

Department of Medicine University of British Columbia Vancouver BC Canada

Department of Neurology Pardubice Regional Hospital Pardubice Czech Republic

Lille Neuroscience et Cognition University Lille INSERM UMR S1172 CHU Lille FHU Imminent Lille France

MellenCenter for Multiple Sclerosis Cleveland Clinic Cleveland OH USA

NeuroRx Research and Montréal Neurological Institute McGill University Montréal QC Canada

Republican Clinical Neurological Center Kazan Russia

Sanofi Cambridge MA USA

Translational Neuroradiology Section National Institute of Neurological Disorders and Stroke Bethesda MD USA

000      

00000naa a2200000 a 4500

001      

bmc21025044

003      

CZ-PrNML

005      

20211026134157.0

007      

ta

008      

211013s2021 xxk f 000 0|eng||

009      

AR

024    7_

$a 10.1016/S1474-4422(21)00237-4 $2 doi

035    __

$a (PubMed)34418400

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxk

100    1_

$a Reich, Daniel S $u Translational Neuroradiology Section, National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA. Electronic address: daniel.reich@nih.gov

245    10

$a Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial / $c DS. Reich, DL. Arnold, P. Vermersch, A. Bar-Or, RJ. Fox, A. Matta, T. Turner, E. Wallström, X. Zhang, M. Mareš, FA. Khabirov, A. Traboulsee, Tolebrutinib Phase 2b Study Group

520    9_

$a BACKGROUND: Tolebrutinib is an oral, CNS-penetrant, irreversible inhibitor of Bruton's tyrosine kinase, an enzyme expressed in B lymphocytes and myeloid cells including microglia, which are major drivers of inflammation in multiple sclerosis. We aimed to determine the dose-response relationship between tolebrutinib and the reduction in new active brain MRI lesions in patients with relapsing multiple sclerosis. METHODS: We did a 16-week, phase 2b, randomised, double-blind, placebo-controlled, crossover, dose-finding trial at 40 centres (academic sites, specialty clinics, and general neurology centres) in ten countries in Europe and North America. Eligible participants were adults aged 18-55 years with diagnosed relapsing multiple sclerosis (either relapsing-remitting or relapsing secondary progressive multiple sclerosis), and one or more of the following criteria: at least one relapse within the previous year, at least two relapses within the previous 2 years, or at least one active gadolinium-enhancing brain lesion in the 6 months before screening. Exclusion criteria included a diagnosis of primary progressive multiple sclerosis or a diagnosis of secondary progressive multiple sclerosis without relapse. We used a two-step randomisation process to randomly assign eligible participants (1:1) to two cohorts, then further randomly assign participants in each cohort (1:1:1:1) to four tolebrutinib dose groups (5, 15, 30, and 60 mg administered once daily as an oral tablet). Cohort 1 received tolebrutinib for 12 weeks, then matched placebo (ie, identical looking tablets) for 4 weeks; cohort 2 received 4 weeks of placebo followed by 12 weeks of tolebrutinib. Participants and investigators were masked for dose and tolebrutinib-placebo administration sequence; investigators, study team members, and study participants did not have access to unmasked data. MRI scans were done at screening and every 4 weeks over 16 weeks. The primary efficacy endpoint was the number of new gadolinium-enhancing lesions detected on the scan done after 12 weeks of tolebrutinib treatment (assessed at week 12 for cohort 1 and week 16 for cohort 2), relative to the scan done 4 weeks previously, and compared with the lesions accumulated during 4 weeks of placebo run-in period in cohort 2. Efficacy data were analysed in a modified intention-to-treat population, using a two-step multiple comparison procedure with modelling analysis. Safety was assessed for all participants who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov (NCT03889639), EudraCT (2018-003927-12), and WHO (U1111-1220-0572), and has been completed. FINDINGS: Between May 14, 2019, and Jan 2, 2020, we enrolled and randomly assigned 130 participants to tolebrutinib: 33 to 5 mg, 32 to 15 mg, 33 to 30 mg, and 32 to 60 mg. 129 (99%) completed the treatment regimen and 126 were included in the primary analysis. At treatment week 12, there was a dose-dependent reduction in the number of new gadolinium-enhancing lesions (mean [SD] lesions per patient: placebo, 1·03 [2·50]; 5 mg, 1·39 [3·20]; 15 mg, 0·77 [1·48]; 30 mg, 0·76 [3·31]; 60 mg, 0·13 [0·43]; p=0·03). One serious adverse event was reported (one patient in the 60 mg group was admitted to hospital because of a multiple sclerosis relapse). The most common non-serious adverse event during tolebrutinib treatment was headache (in one [3%] of 33 in the 5 mg group; three [9%] of 32 in the 15 mg group; one [3%] of 33 in the 30 mg group; and four [13%] of 32 in the 60 mg group). No safety-related discontinuations or treatment-related deaths occurred. INTERPRETATION: 12 weeks of tolebrutinib treatment led to a dose-dependent reduction in new gadolinium-enhancing lesions, the 60 mg dose being the most efficacious, and the drug was well tolerated. Reduction of acute inflammation, combined with the potential to modulate the immune response within the CNS, provides a scientific rationale to pursue phase 3 clinical trials of tolebrutinib in patients with relapsing and progressive forms of multiple sclerosis. FUNDING: Sanofi.

650    _2

$a dospělí $7 D000328

650    _2

$a proteinkinasa BTK $x antagonisté a inhibitory $7 D000077329

650    _2

$a centrální nervový systém $x diagnostické zobrazování $x účinky léků $x imunologie $x patologie $7 D002490

650    _2

$a klinické křížové studie $7 D018592

650    _2

$a vztah mezi dávkou a účinkem léčiva $7 D004305

650    _2

$a dvojitá slepá metoda $7 D004311

650    _2

$a ženské pohlaví $7 D005260

650    _2

$a lidé $7 D006801

650    _2

$a zánět $x diagnostické zobrazování $x farmakoterapie $x imunologie $x patologie $7 D007249

650    _2

$a magnetická rezonanční tomografie $7 D008279

650    _2

$a mužské pohlaví $7 D008297

650    _2

$a lidé středního věku $7 D008875

650    _2

$a relabující-remitující roztroušená skleróza $x diagnostické zobrazování $x farmakoterapie $x imunologie $x patologie $7 D020529

650    12

$a hodnocení výsledků zdravotní péče $7 D017063

650    _2

$a inhibitory proteinkinas $x aplikace a dávkování $x škodlivé účinky $x farmakokinetika $x farmakologie $7 D047428

650    _2

$a recidiva $7 D012008

650    _2

$a mladý dospělý $7 D055815

655    _2

$a klinické zkoušky, fáze II $7 D017427

655    _2

$a časopisecké články $7 D016428

655    _2

$a multicentrická studie $7 D016448

655    _2

$a randomizované kontrolované studie $7 D016449

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Arnold, Douglas L $u NeuroRx Research and Montréal Neurological Institute, McGill University, Montréal, QC, Canada

700    1_

$a Vermersch, Patrick $u Lille Neuroscience et Cognition, University Lille, INSERM UMR-S1172, CHU Lille, FHU Imminent, Lille, France

700    1_

$a Bar-Or, Amit $u Center for Neuroinflammation and Neurotherapeutics and the Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA

700    1_

$a Fox, Robert J $u MellenCenter for Multiple Sclerosis, Cleveland Clinic, Cleveland, OH, USA

700    1_

$a Matta, Andre $u Sanofi, Cambridge, MA, USA

700    1_

$a Turner, Timothy $u Sanofi, Cambridge, MA, USA

700    1_

$a Wallström, Erik $u Sanofi, Cambridge, MA, USA

700    1_

$a Zhang, Xinyan $u Sanofi, Cambridge, MA, USA

700    1_

$a Mareš, Miroslav $u Department of Neurology, Pardubice Regional Hospital, Pardubice, Czech Republic

700    1_

$a Khabirov, Farit A $u Republican Clinical Neurological Center, Kazan, Russia

700    1_

$a Traboulsee, Anthony $u Department of Medicine, University of British Columbia, Vancouver, BC, Canada

710    2_

$a Tolebrutinib Phase 2b Study Group

773    0_

$w MED00006921 $t The Lancet. Neurology $x 1474-4465 $g Roč. 20, č. 9 (2021), s. 729-738

856    41

$u https://pubmed.ncbi.nlm.nih.gov/34418400 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y p $z 0

990    __

$a 20211013 $b ABA008

991    __

$a 20211026134203 $b ABA008

999    __

$a ok $b bmc $g 1714205 $s 1145551

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2021 $b 20 $c 9 $d 729-738 $e - $i 1474-4465 $m Lancet neurology $n Lancet Neurol $x MED00006921

GRA    __

$a Z99 NS999999 $p Intramural NIH HHS $2 United States

LZP    __

$a Pubmed-20211013